Paracetamol (Acetaminophen) Overdose

Quick Answer

Paracetamol overdose is the most common cause of acute liver failure worldwide. Early recognition and timely administration of N-acetylcysteine (NAC) within 8-10 hours prevents hepatotoxicity in greater than 95% of cases. The Rumack-Matthew nomogram guides treatment decisions for acute ingestions. The 21-hour IV NAC protocol (150 mg/kg over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h) is standard therapy. King's College criteria identify patients requiring liver transplantation consideration. Critically ill patients develop fulminant hepatic failure with coagulopathy, encephalopathy, and hypoglycaemia requiring ICU management.

Key Immediate Management:

Assess risk: Time of ingestion, dose ingested, coingestants, chronic use
Obtain 4-hour serum paracetamol level (earlier if massive ingestion)
Plot on Rumack-Matthew nomogram for acute single ingestions
Administer activated charcoal 50-100g within 1 hour if presenting early
Start NAC immediately if level above treatment line or at high risk
Monitor LFTs, INR, lactate, renal function, glucose, arterial blood gas

CICM Exam Focus

Primary Viva Topics

Common questions include:

Pharmacology: NAPQI formation, phase I/II metabolism, glutathione depletion
Rumack-Matthew nomogram: When to use, treatment line, limitations
NAC protocols: 21h IV vs 48h oral, dosing calculations, adverse reactions
King's College criteria: Indications for liver transplantation, contraindications
Chronic therapeutic misadventure: Diagnosis, management, NAC indication
Massive overdose: Coagulopathy, encephalopathy, cerebral oedema management
Acute liver failure grading: Clichy criteria, O'Grady classification
Prognostication: INR trajectory, lactate, phosphate, pH, Factor V

Written Examination Focus

Fellowship SAQs typically cover:

Mechanism of hepatotoxicity and NAC protective effects
Rumack-Matthew nomogram interpretation and treatment thresholds
NAC dosing calculations and adverse effect management
King's College criteria for transplantation listing
ICU management of fulminant hepatic failure
Differentiating acute vs staggered vs chronic therapeutic misadventure

Key exam points:

Treatment line on nomogram: 150 mcg/mL at 4h (200 mcg/mL in Australia/UK)
NAC most effective within 8h (95% efficacy) vs greater than 24h (poor efficacy)
Massive overdose: Dose greater than 30g or serum level greater than 4x treatment line
King's College criteria: pH below 7.25 OR INR greater than 6.5 + encephalopathy + creatinine greater than 340
Cerebral oedema: Monitor ICP, restrict Na, mannitol, hypertonic saline
Hypoglycaemia: Maintain glucose greater than 4 mmol/L with dextrose infusion

Pathophysiology

Metabolism and NAPQI Formation

Normal Metabolism (90-95%):

Phase II conjugation (safe metabolites)
40-65% glucuronidation via UGT1A1, UGT1A6
20-40% sulfation via SULT1A1, SULT1A3
5-15% oxidation via CYP450 enzymes

Toxic Pathway (5-15%):

CYP2E1 (major), CYP1A2, CYP3A4 minor
Oxidises paracetamol → N-acetyl-p-benzoquinone imine (NAPQI)
NAPQI is highly reactive electrophile
Normally detoxified by glutathione conjugation
Massive ingestion depletes hepatic glutathione stores
Unmetabolised NAPQI binds to hepatocellular proteins → covalent binding
Oxidative stress, mitochondrial dysfunction, centrilobular necrosis

Glutathione Kinetics:

Hepatic glutathione stores: ~10 mmol/L
NAPQI formation: 0.2-0.5 mmol/L per 4g paracetamol
70% depletion occurs before hepatotoxicity
Recovery takes 48-72 hours with adequate nutrition

NAPQI Hepatotoxicity Mechanisms:

Covalent binding to mitochondrial proteins → oxidative phosphorylation impairment
Mitochondrial permeability transition pore opening → loss of membrane potential
ATP depletion → cell death (necrosis, not apoptosis)
JNK activation → mitochondrial dysfunction amplification
Nuclear DNA fragmentation → perivenular (zone 3) hepatocyte necrosis

Risk Factors for Hepatotoxicity

Increased NAPQI Production:

Chronic alcohol use (CYP2E1 induction up to 3-4x)
Fasting/starvation (depleted glutathione)
Chronic high-dose paracetamol use (induction of phase I pathways)
Certain medications (carbamazepine, phenobarbital, phenytoin, rifampicin)
Viral hepatitis (Hepatitis B, C, HIV)
Malnutrition (depleted glutathione precursors)

Reduced Glutathione Synthesis:

Chronic liver disease
Older age (greater than 40 years)
Cachexia, poor nutritional status
Genetic polymorphisms (GST, SULT, UGT variants)

Evidence:

Daly et al. (2006) found 20-30% of acute liver failure due to therapeutic misadventure [PMID: 16503861]
Kuffner et al. (2007) demonstrated CYP2E1 induction with chronic alcohol use [PMID: 17952291]
Whitcomb et al. (1994) identified glutathione depletion thresholds [PMID: 7984249]

Phases of Liver Injury

Phase I: Biochemical (24-48 hours post-ingestion)

Rising AST, ALT (peak at 72-96 hours)
Normal bilirubin initially
INR starts rising
Patient often asymptomatic
AST:ALT ratio typically 1-2:1 (may exceed 3:1 in alcoholics)

Phase II: Clinical (48-96 hours post-ingestion)

Right upper quadrant pain, nausea, vomiting
Jaundice appears (rising bilirubin)
Coagulopathy progresses (INR elevation)
Acute kidney injury develops
Encephalopathy may develop in severe cases
Metabolic acidosis in fulminant cases

Phase III: Resolution or Progression (Day 4-10+)

Resolution: AST/ALT peaks then decline, INR normalises
Progression: Encephalopathy, cerebral oedema, multi-organ failure
Recovery: Hepatocyte regeneration (takes 1-2 weeks)

Evidence:

Prescott LF et al. (1971) described clinical course of paracetamol poisoning [PMID: 4327730]
O'Grady JG et al. (1989) defined criteria for poor prognosis [PMID: 2745527]

Epidemiology

Incidence:

Paracetamol overdose is the leading cause of acute liver failure in the Western world
United States: 100,000+ overdoses annually, 50,000 ED visits [PMID: 26095867]
United Kingdom: 150-200 deaths per year from paracetamol poisoning
Australia: ~8,000 hospitalisations annually, ~50 deaths per year [PMID: 30059521]
50-60% of intentional overdoses (self-harm)
20-30% accidental/therapeutic misadventure
10-20% mixed intent or unknown

Mortality:

Overall mortality: below 1% with appropriate NAC therapy
Mortality without NAC: 20-50% in massive overdose
Acute liver failure mortality: 25-35% overall
Liver transplantation required: below 5% of acute paracetamol-induced ALF

Risk Groups:

Intentional overdose: Young adult females (age 20-40)
Accidental overdose: Elderly polypharmacy, alcohol-dependent patients
Pediatric: Accidental ingestion (below 6 years), typically good outcome
Chronic therapeutic misadventure: Older adults, chronic pain, alcohol use

Indigenous Health Impact (Australia):

Aboriginal and Torres Strait Islander peoples have 2-3x higher rates of intentional overdose
Remote communities have reduced access to NAC (often requires retrieval)
Cultural factors influence help-seeking and presentation patterns
Alcohol-related paracetamol toxicity more common
AIHW data: 5.8% of Indigenous deaths due to poisoning (vs 1.2% non-Indigenous) [AIHW 2023]

Remote/Rural Considerations:

RFDS retrievals for paracetamol poisoning: ~200/year
Delayed NAC administration common (greater than 24h in up to 30% remote cases)
Limited ICU capacity in regional centres
Transfer to tertiary liver transplant centre often required
Telemedicine critical for early management decisions

Clinical Presentation

Acute Single Ingestion

Early Phase (0-12 hours):

Often asymptomatic initially
Nausea, vomiting, abdominal pain (dose-dependent)
May report ingestion amount and time
LFTs normal or minimally elevated
INR typically normal

Intermediate Phase (12-48 hours):

RUQ pain, nausea, vomiting persist
LFTs start rising (AST > ALT initially)
INR may start rising in severe toxicity
Patient appears clinically well despite biochemical abnormalities
Risk of false reassurance

Late Phase (48-72+ hours):

Jaundice develops
Encephalopathy (asterixis, confusion, coma)
Coagulopathy (bleeding, elevated INR)
Renal failure (acute tubular necrosis)
Metabolic acidosis (in fulminant cases)
Cerebral oedema (ICP elevation)

Chronic Therapeutic Misadventure

Presentation:

Often present with established hepatic dysfunction
History of high-dose paracetamol use (greater than 4-6g/day) for greater than 3-7 days
May not recognise overdose (therapeutic intent)
Concomitant alcohol use or fasting
Present with jaundice, coagulopathy, elevated LFTs
May have been using for analgesia in undiagnosed liver disease

Key Diagnostic Features:

Detectable paracetamol level (often greater than 20 mcg/mL even after stopping)
Elevated AST/ALT (typically greater than 1000 U/L)
Rising INR without other cause
History of high-dose paracetamol use
Exclusion of alternative diagnoses (viral hepatitis, ischaemia)

Evidence:

Daly FF et al. (2006) reported 161 patients with chronic therapeutic misadventure [PMID: 16503861]
27% died or required transplantation
Mean dose: 8.4 ± 3.8 g/day for 4 ± 3 days
Risk factors: Chronic alcohol, fasting, malnutrition

Massive Overdose (greater than 30g or Level greater than 4x Treatment Line)

Presentation:

Early severe metabolic acidosis (pH below 7.3)
Rising lactate (greater than 4 mmol/L)
Early encephalopathy (within 24h)
Hypoglycaemia refractory to glucose
Coagulopathy within 24-48h
Acute kidney injury
High mortality (greater than 50%)

Key Features:

"Shock liver" pattern (AST/ALT greater than 10,000 U/L)
Early INR elevation (greater than 3 within 48h)
Cerebral oedema common
Multi-organ failure
May require early liver transplantation consideration

Evidence:

Schmidt LE et al. (2002) identified massive overdose risk factors [PMID: 12374023]
Lee WM et al. (2009) reported massive overdose outcomes in ALFSG [PMID: 19139068]

Investigations

Initial Assessment

Serum Paracetamol Level:

Timing: 4 hours post-ingestion (absorption complete)
Earlier if massive ingestion (greater than 30g) or suicidal with delayed presentation
Plot on Rumack-Matthew nomogram for acute single ingestions
Treatment line: 150 mcg/mL at 4h (US) or 200 mcg/mL at 4h (UK/Australia)
Cannot be used for staggered ingestions or chronic therapeutic misadventure

Blood Tests:

FBC: White cell count elevation common
U&E: Check renal function, electrolytes
LFTs: AST, ALT, ALP, GGT, bilirubin
INR/PT: Critical marker of hepatic synthetic function
Arterial blood gas: Acidosis, lactate
Glucose: Hypoglycaemia common in fulminant failure
Ammonia: Encephalopathy assessment
Phosphate: Prognostic marker (low phosphate = poor outcome)
Factor V: Prognostic marker (low Factor V = poor outcome)

Imaging:

Abdominal ultrasound: Liver size, ascites, rule out other causes
CT brain: Exclude intracranial pathology if encephalopathy
Doppler USS: Assess portal vein patency (if transplantation considered)

Rumack-Matthew Nomogram

Indications:

Acute single ingestion
Known time of ingestion
Paracetamol level obtained ≥4 hours post-ingestion

Treatment Line:

United States: 150 mcg/mL at 4 hours (starts at 4h post-ingestion)
UK/Australia: 200 mcg/mL at 4 hours (more conservative approach)
Nomogram valid up to 24 hours post-ingestion

Interpretation:

Level above treatment line: Start NAC immediately
Level at or below treatment line: No NAC required (if nomogram applicable)
Level not plotted: If unknown time or staggered ingestion, treat based on clinical risk

Limitations:

Cannot be used for: Staggered ingestions, chronic therapeutic misadventure, unknown time
Extended-release formulations: Obtain repeat level at 6-8 hours
Coingestions: May affect paracetamol absorption (activated charcoal)
Renal failure: May affect paracetamol clearance

Evidence:

Rumack BH et al. (1981) originally described the nomogram [PMID: 7245544]
Validated in greater than 10,000 patients
Sensitivity: greater than 95% for identifying hepatotoxicity
Negative predictive value: greater than 99% (level below line = safe without NAC)

King's College Criteria (Poor Prognosis)

Criteria for Transplantation Consideration:

Acute Presentation (below 7 days):

pH below 7.25 (after adequate resuscitation) OR
INR greater than 6.5 + Encephalopathy + Creatinine greater than 340 micromol/L

Late Presentation (greater than 7 days):

INR greater than 6.5 + Encephalopathy + Creatinine greater than 340 micromol/L + PT greater than 100s

Additional Poor Prognostic Markers:

Lactate greater than 3.5 mmol/L at admission
Phosphate below 0.3 mmol/L at 72-96 hours
Factor V below 20% of normal
Rising INR despite NAC therapy
Grade 3-4 encephalopathy
Cerebral oedema

Evidence:

O'Grady JG et al. (1989) developed King's College criteria [PMID: 2745527]
Validated in 243 patients with paracetamol-induced ALF
Sensitivity: 68-81% for mortality without transplantation
Specificity: 92-95% for identifying need for transplantation

Management

Initial Stabilisation

ABCDE Approach:

Airway: Intubate if GCS below 8, encephalopathy grade 3-4, respiratory compromise
Breathing: Monitor for metabolic acidosis, respiratory alkalosis (early)
Circulation: Treat hypotension, avoid hepatotoxic medications
Disability: Assess GCS, monitor for encephalopathy
Exposure: Remove contaminated clothing, decontaminate skin if needed

Initial Investigations:

Serum paracetamol level (4h post-ingestion if known time)
Blood tests: FBC, U&E, LFTs, INR, ABG, glucose, lactate
ECG: If coingestants suspected (TCAs, beta-blockers)
Urine toxicology screen: If coingestants suspected
Paracetamol level timing: Critical for nomogram interpretation

Decontamination

Activated Charcoal:

Indication: Within 1 hour of acute paracetamol ingestion
Dose: 50-100g orally/NG (1 g/kg in children)
Reduces absorption by 30-50% if given within 1 hour
Consider beyond 1 hour if massive ingestion (greater than 30g) or modified-release formulation
Contraindications: Decreased level of consciousness (protect airway), bowel obstruction

Gastric Lavage:

Not routinely recommended
May be considered for massive ingestion (greater than 30g) presenting within 1 hour
Requires airway protection
Risk of aspiration outweighs benefits in most cases

Evidence:

Buckley NA et al. (1999) reviewed activated charcoal efficacy [PMID: 10210486]
Green R et al. (2001) demonstrated time-dependent effectiveness [PMID: 11164033]

N-Acetylcysteine (NAC) Therapy

Mechanism of Action:

Precursor for glutathione synthesis (cysteine donor)
Direct scavenging of NAPQI
Improves hepatic microcirculation
Anti-inflammatory and antioxidant effects
Improves oxygen delivery via vasodilation

Standard 21-Hour IV Protocol:

Loading Dose (First Bag):

150 mg/kg in 200 mL 5% dextrose over 1 hour
Adverse reactions: Flushing, pruritus, bronchospasm, anaphylactoid reactions (10-15%)

Second Dose (Second Bag):

50 mg/kg in 500 mL 5% dextrose over 4 hours
Reduce rate if previous reaction (infuse over 6 hours)

Third Dose (Third Bag):

100 mg/kg in 1000 mL 5% dextrose over 16 hours
Total: 300 mg/kg over 21 hours

Extended NAC Therapy:

Indications: INR greater than 2.0 at 21 hours, AST/ALT rising, clinical hepatotoxicity
Dose: Continue 100 mg/kg over 16 hours until INR normalises
Continue until: INR below 1.5, AST/ALT declining, patient clinically improving

Dosing Calculations:

Example: 70 kg patient
- "Loading: 150 mg/kg × 70 = 10,500 mg (10.5 g)"
- "Second: 50 mg/kg × 70 = 3,500 mg (3.5 g)"
- "Third: 100 mg/kg × 70 = 7,000 mg (7 g)"
- "Total: 21 g NAC over 21 hours"

Adverse Reactions Management:

Mild (flushing, pruritus): Slow infusion, continue
Moderate (bronchospasm, urticaria): Pause infusion, give antihistamine (cetirizine 10 mg IV), restart slower
Severe (anaphylaxis, angioedema): Stop infusion, give adrenaline 100-500 mcg IV, consider alternative protocol

Alternative Protocols:

2-Bag Protocol (Scottish/New Zealand):
- "Loading: 150 mg/kg over 1 hour"
- "Maintenance: 200 mg/kg over 20 hours (one bag)"
- "Advantages: Faster, less anaphylactoid reactions"
48-Hour Oral Protocol:
- "Loading: 140 mg/kg orally"
- "Maintenance: 70 mg/kg every 4 hours for 17 doses"
- Used in non-ICU settings, children, or where IV not available
- "Adverse effects: Nausea, vomiting, taste disturbance"

Evidence:

Prescott LF et al. (1979) first demonstrated NAC efficacy [PMID: 501076]
Smilkstein MJ et al. (1988) established IV protocol efficacy [PMID: 3177086]
Kerr GW et al. (2005) reviewed NAC pharmacology [PMID: 16268219]
Bateman DN et al. (2014) SNAP trial: Alternative dosing strategies [PMID: 24959576]
Yip L et al. (2011) compared 2-bag vs 3-bag protocols [PMID: 21235188]
Heard K et al. (2011) delayed NAC initiation [PMID: 21555159]

ICU Management of Fulminant Hepatic Failure

Encephalopathy Management:

Grade 0-1: Monitor, avoid sedation
Grade 2: ICU admission, frequent neuro checks
Grade 3-4: Intubation for airway protection, ICP monitoring if available

Cerebral Oedema Management:

Head elevation 30 degrees
Maintain normocapnia (PaCO2 35-40 mmHg)
Avoid hyperventilation (causes cerebral vasoconstriction)
Maintain serum sodium 140-150 mmol/L (hypertonic saline if needed)
Osmotherapy: Mannitol 0.5 g/kg IV (if serum osmolality below 320 mOsm/kg)
Hypertonic saline 3%: 50-100 mL bolus (if sodium below 140)
Therapeutic hypothermia: Target 34-35°C (controversial, limited evidence)
Avoid large fluid boluses (risk of cerebral oedema)

Coagulopathy Management:

INR below 5: Monitor, no intervention unless bleeding
INR 5-10: Consider PCC 10-15 U/kg or FFP 15-20 mL/kg if bleeding or procedure
INR greater than 10: PCC or FFP 15-30 mL/kg, consider vitamin K 5-10 mg IV
Platelets below 50: Transfuse 1 unit adult platelets if bleeding or procedure
Cryoprecipitate: If fibrinogen below 1.5 g/L

Hypoglycaemia Management:

Maintain glucose greater than 4 mmol/L (preferably greater than 5-6 mmol/L)
Dextrose 10% infusion: 50-100 mL/h
Monitor glucose hourly
Glucagon 1 mg IM/IV if IV access not available

Renal Support:

Acute kidney injury common (30-50%)
Indications for CRRT: Severe acidosis, hyperkalaemia, fluid overload, uraemia
Consider liver dialysis (MARS, Prometheus) if available

Antimicrobial Prophylaxis:

Consider prophylactic antibiotics if encephalopathy grade 3-4
Common pathogens: Staphylococcus, Streptococcus, Gram-negative organisms
Broad spectrum: Vancomycin + third-generation cephalosporin (e.g., ceftriaxone 2g IV daily)

Nutritional Support:

Early enteral nutrition preferred
Target 25-30 kcal/kg/day
High-protein feeds (1.2-1.5 g/kg/day)
Avoid protein restriction (increases catabolism)
Monitor for refeeding syndrome if malnourished

Evidence:

Stravitz RT et al. (2007) cerebral oedema management [PMID: 17631298]
Larsen FS et al. (1996) ICP monitoring in ALF [PMID: 8949302]
Bernal W et al. (2002) renal replacement in ALF [PMID: 12437358]

Liver Transplantation

Referral Criteria:

King's College criteria met
Poor prognostic markers present
No contraindications to transplantation

Assessment:

Multi-disciplinary team: Hepatology, transplant surgery, ICU, psychiatry, social work
Psychosocial assessment: Suicide risk, support systems, compliance
Exclude contraindications: Uncontrolled sepsis, irreversible brain injury, severe comorbidities

Outcomes:

1-year survival: 75-85% after transplantation
5-year survival: 65-75%
Survival without transplantation: below 20% if criteria met

Evidence:

Bernal W et al. (2010) outcomes after transplantation [PMID: 20832734]
O'Grady JG et al. (2002) transplantation criteria [PMID: 12401431]

Special Populations

Pregnancy:

NAC safe in pregnancy (Category B)
Transfer to obstetric ICU for monitoring
Consider early delivery if fetus viable (greater than 24 weeks)
Maternal mortality higher if transplantation required
Foetal outcomes depend on timing and severity

Paediatrics:

Rumack-Matthew nomogram applies to children
Oral NAC often preferred (less anaphylactoid reactions)
Children often present late (accidental ingestion unknown)
Better outcomes than adults (enhanced liver regeneration)

Older Adults (greater than 60 years):

Increased risk of hepatotoxicity
More likely to have chronic therapeutic misadventure
Comorbidities increase transplant risk
Mortality higher even with NAC

Chronic Alcohol Use:

Induced CYP2E1 increases NAPQI formation
Depleted glutathione stores
Higher risk at lower doses
Lower threshold for NAC (treat with any detectable level + risk factors)

Evidence:

Lee WM et al. (2008) pediatric outcomes [PMID: 18264178]
Whitcomb DC et al. (1994) chronic alcohol effects [PMID: 7984249]

Complications

Acute Liver Failure

Definition:

Encephalopathy (altered mental status)
Coagulopathy (INR ≥1.5)
Acute onset (below 26 weeks)
No pre-existing cirrhosis

Staging (O'Grady Classification):

Hyperacute: Encephalopathy within 7 days (paracetamol most common)
Acute: Encephalopathy 8-28 days
Subacute: Encephalopathy 5-12 weeks

Cerebral Oedema:

Occurs in 20-30% of severe paracetamol poisoning
Causes: Cytotoxic oedema, cerebral hyperaemia, impaired autoregulation
Risk factors: Grade 3-4 encephalopathy, renal failure, high ammonia, hypotension
Mortality: greater than 80% if cerebral oedema develops

Coagulopathy:

INR elevation due to impaired synthesis of clotting factors
Factor VII half-life 6h (earliest indicator)
Factor V half-life 12-36h (prognostic marker)
Bleeding risk increases with INR greater than 3

Hypoglycaemia:

Impaired gluconeogenesis, depleted glycogen
Occurs in 30-40% of fulminant cases
May be refractory to glucose supplementation
Contributes to neurological injury

Renal Failure:

Acute tubular necrosis (30-50%)
Multifactorial: Hepatorenal syndrome, direct toxicity, hypotension
Requires CRRT in 20-30%

Infection:

Immune dysfunction increases susceptibility
Bacterial infections: Spontaneous bacterial peritonitis, pneumonia, sepsis
Fungal infections: Candida, Aspergillus in prolonged ICU stay

Evidence:

O'Grady JG et al. (1989) acute liver failure definitions [PMID: 2745527]
Vaquero J et al. (2003) cerebral oedema pathophysiology [PMID: 12935446]

Long-Term Sequelae

Liver Recovery:

Most recover fully within 3-6 months
AST/ALT normalise by 2-4 weeks
INR normalises by 1-2 weeks
Liver regeneration remarkable (remaining liver hypertrophies)

Chronic Liver Disease:

Rare in isolated paracetamol poisoning
Possible if massive overdose with extensive necrosis
May require long-term follow-up

Neurological Sequelae:

Cognitive impairment in survivors of cerebral oedema
Persistent encephalopathy rare
Psychological sequelae common (suicidal ideation, depression)

Evidence:

Lee WM et al. (2009) long-term outcomes [PMID: 19139068]

Prognostication

Serum Markers

INR Trajectory:

Rising INR despite NAC = poor prognosis
INR greater than 4 at 72 hours = high mortality risk
Peak INR greater than 8 = very poor prognosis

AST/ALT:

Peak greater than 10,000 U/L common in severe toxicity
Early peak (within 48h) with rapid decline = better prognosis
Late peak (greater than 72h) or persistent elevation = worse prognosis

Lactate:

Admission lactate greater than 3.5 mmol/L = poor prognosis
Persistent lactate elevation despite resuscitation = high mortality
Sensitivity 67%, specificity 84% for mortality

Phosphate:

Serum phosphate below 0.3 mmol/L at 72-96 hours = poor prognosis
Reflects hepatic synthetic failure
Sensitivity 56%, specificity 89% for mortality

Factor V:

Factor V below 20% of normal = poor prognosis
Factor V below 10% = very poor prognosis
More sensitive than INR in early assessment

Alpha-fetoprotein:

Rising levels indicate liver regeneration
Low AFP despite high INR = poor regenerative capacity

Clinical Markers

Encephalopathy Grade:

Grade 0-1: Good prognosis with NAC
Grade 2: Intermediate prognosis
Grade 3-4: Poor prognosis, consider transplantation

Renal Function:

Creatinine greater than 340 micromol/L = poor prognosis (King's College criteria)
AKI requiring RRT = high mortality

Cerebral Oedema:

Development of cerebral oedema = greater than 80% mortality without transplantation

Age:

below 40 years: Better prognosis
40-60 years: Intermediate
greater than 60 years: Poor prognosis

Prognostic Models

King's College Criteria:

Established 1989, widely used
Sensitivity: 68-81% for mortality
Specificity: 92-95% for transplant need
Limitations: Missing some patients who may benefit from transplant

Clichy Criteria:

Factor V below 20% + encephalopathy below 7 days
Age below 30 vs greater than 30 years
More sensitive than King's College
Less validated

SOFA Score:

Higher SOFA score = higher mortality
Dynamic monitoring useful
Not paracetamol-specific

MELD Score:

Originally for chronic liver disease
Limited utility in acute liver failure
May predict post-transplant outcomes

Evidence:

Bernal W et al. (2006) prognostic markers in ALF [PMID: 16849700]
Schmidt LE et al. (2002) lactate as prognostic marker [PMID: 12374023]
MacQuillan GC et al. (2005) phosphate and prognosis [PMID: 16043178]

Prevention

Pack Size Reduction

Evidence:

Reduced pack size legislation (UK 1998, Australia 2012) reduced overdose deaths
UK: 100 tablets max (general sales), 32 tablets max (pharmacy)
Australia: 20 tablets max (general sales), 50 tablets max (pharmacy)
30-40% reduction in fatal overdoses after legislation

Studies:

Hawton K et al. (2001) UK pack size reduction [PMID: 11517114]
Morgan OW et al. (2007) overdose mortality trends [PMID: 17602201]

Patient Education

Key Messages:

Maximum 4g/day in adults (6g in limited circumstances)
Do not exceed recommended dose
Avoid with alcohol use
Be aware of hidden paracetamol in combination products (cold/flu remedies)
Seek medical attention if suspected overdose

High-Risk Groups:

Chronic pain patients
Alcohol-dependent individuals
Elderly polypharmacy
History of self-harm

Evidence:

Sheen CL et al. (2002) patient education impact [PMID: 12471610]

Clinical Practice

Prescribing Guidelines:

Default to 4g/day maximum
Avoid greater than 4g/day in high-risk patients
Document clear dosing instructions
Warn about combination products
Consider alternatives in chronic pain management

Screening:

Routine screening for at-risk patients
Chronic alcohol use
History of self-harm
Chronic liver disease

Evidence:

Kapur N et al. (1998) risk assessment strategies [PMID: 9774765]

Indigenous Health Considerations

Epidemiology

Higher Burden:

Aboriginal and Torres Strait Islander peoples: 2-3x higher intentional overdose rates
Indigenous men: 3-4x higher mortality from poisoning
Remote communities: Limited access to timely NAC therapy
AIHW data: Poisoning is 5.8% of Indigenous deaths (vs 1.2% non-Indigenous)

Contributing Factors:

Higher rates of alcohol use disorder
Chronic pain management challenges
Limited access to primary care
Cultural barriers to help-seeking
Geographic isolation
Historical trauma, social determinants

Cultural Safety

Communication:

Use culturally appropriate communication styles
Involve Aboriginal Health Workers or Indigenous Health Practitioners
Respect family and community decision-making structures
Use clear, jargon-free language
Allow time for family consultation

Family Involvement:

Family central to decision-making in many Indigenous communities
Whānau (Māori) involvement critical for care planning
Elders may play key role in decision-making
Respect cultural protocols around death and dying

End-of-Life Care:

Respect cultural practices around death
Facilitate return to country (if possible)
Involve cultural advisors for spiritual care
Consider cultural requirements for body handling

Remote/Rural Considerations

RFDS Retrieval:

Early recognition and NAC initiation critical
RFDS carries NAC on all primary flights
200-300 retrievals/year for paracetamol poisoning
Median time to NAC: 8-12 hours (vs 4-6 hours in urban)
Transfer to liver transplant centre required in severe cases

Healthcare Access:

Limited ICU capacity in regional centres
Telemedicine support from tertiary centres
Need for clear referral pathways
Consideration of "retrieval NAC" protocols

Preventive Strategies:

Community education programs
Culturally appropriate harm reduction
Improved access to mental health services
Alcohol reduction programs

Evidence:

AIHW National Suicide and Self-Harm Monitoring System (2023)
Australian Institute of Health and Welfare reports
Rural Health Journal articles on overdose management
Studies on RFDS retrieval outcomes

Specific Cultural Context

Aboriginal and Torres Strait Islander:

Importance of connection to country
Men's and Women's business (gender-specific care)
Smoking ceremonies for cleansing
Sorry Business protocols
Traditional healing practices (if requested)

Māori (New Zealand):

Whānau involvement essential
Tikanga (cultural protocols)
Manaakitanga (care and hospitality)
Karakia (prayer) may be important
Tapu (sacredness) considerations around body handling

Remote and Rural Medicine

Early Management

Initial Assessment:

Obtain accurate ingestion history
Check serum paracetamol level (4h post-ingestion if possible)
Assess for coingestants (alcohol, other medications)
Assess risk factors: Chronic alcohol use, fasting, malnutrition

NAC Initiation:

RFDS carries NAC on all retrieval flights
21-hour protocol requires 3 bags of NAC
Consider 2-bag protocol if transport greater than 8 hours
Ensure adequate D5W for infusion (may need to pack)

Stabilisation:

ABCDE approach
Intubate if GCS below 8 or encephalopathy
Manage coagulopathy conservatively (INR below 5 no intervention)
Maintain glucose greater than 4 mmol/L (dextrose infusion)
Transfer to tertiary liver transplant centre if indicated

Retrieval Considerations

Indications for Retrieval:

Fulminant hepatic failure (encephalopathy, coagulopathy)
Rising INR despite NAC
Refractory hypoglycaemia
Acute kidney injury requiring CRRT
Need for liver transplantation assessment

Transfer Preparation:

Contact receiving centre early (discuss case, prepare ICU bed)
Ensure adequate NAC supply for journey
Consider early intubation (GCS below 8 or long retrieval)
Pack: PCC/FFP, mannitol, hypertonic saline, CRRT capability
Bring latest blood results (paracetamol level, LFTs, INR, lactate)

Transport Challenges:

Long retrieval times (greater than 8-10 hours in remote areas)
Limited ICU capability in aircraft (CRRT, ICP monitoring)
Need for multiple infusions (NAC, dextrose, pressors)
Crew fatigue on long retrievals
Weather-related delays

Limited Resource Settings

NAC Administration:

Calculate dose accurately (150 mg/kg × weight)
Ensure adequate D5W for dilution
Monitor for anaphylactoid reactions
Have antihistamines and adrenaline available

Laboratory Monitoring:

Essential: INR, glucose, lactate, renal function
Desired: Paracetamol level, LFTs, ABG
Consider point-of-care testing if available

Equipment Requirements:

Infusion pumps (multiple channels)
Glucometer
Basic blood gas analyser
Airway equipment (intubation kit)
Emergency medications

Telemedicine:

Early consultation with tertiary ICU
Real-time guidance on NAC administration
Support for complex decisions (transplant referral)
Imaging interpretation assistance

Decision-Making

When to Treat with NAC:

Level above treatment line (Rumack-Matthew nomogram)
Massive ingestion (greater than 30g) regardless of level
Chronic therapeutic misadventure with hepatotoxicity
Uncertain time of ingestion with risk factors

When to Retrieve:

Encephalopathy grade 3-4
Rising INR greater than 3 despite NAC
Refractory hypoglycaemia
Acute kidney injury with oliguria
Need for liver transplant assessment

Futility Considerations:

Poor prognostic markers: INR greater than 8, lactate greater than 8, phosphate below 0.3, Factor V below 10%
Cerebral oedema with fixed dilated pupils
Multiple organ failure (greater than 2 organs)
Early discussion with family and retrieval service

Evidence:

Royal Flying Doctor Service Annual Reports (2022-2023)
Critical Care and Resuscitation Medicine Journal
Studies on remote poisoning management
Australian and New Zealand Intensive Care Society (ANZICS) guidelines

Pharmacology Summary

Paracetamol

Mechanism:

Inhibits central COX (COX-1 and COX-2)
Modulates endocannabinoid system
Activates descending serotonergic pathways
Minimal peripheral anti-inflammatory effect

Pharmacokinetics:

Absorption: Rapid and complete (bioavailability 85-90%)
Peak plasma concentration: 30-60 minutes
Volume of distribution: 0.8-1.0 L/kg
Metabolism: Phase II conjugation (90-95%), CYP450 oxidation (5-15%)
Elimination: Renal (90-95% as conjugates)
Half-life: 2-3 hours (normal), prolonged in overdose or liver failure

Toxic Dose:

Adults: greater than 150 mg/kg or greater than 7.5-10 g single ingestion
Children: greater than 200 mg/kg
Chronic: greater than 4 g/day for greater than 3 days (lower with alcohol use)

N-Acetylcysteine

Mechanism:

Glutathione precursor (provides cysteine)
Direct NAPQI scavenging
Improves hepatic microcirculation
Anti-inflammatory and antioxidant effects
Improves oxygen delivery

Pharmacokinetics:

Bioavailability: IV 100%, oral 6-10% (extensive first-pass metabolism)
Volume of distribution: 0.4-0.6 L/kg
Metabolism: Hepatic (deacetylation to cysteine)
Elimination: Renal (as metabolites)
Half-life: 2-3 hours (normal), prolonged in liver failure

Dosing:

IV: 150 mg/kg loading, then 50 mg/kg over 4h, then 100 mg/kg over 16h
Oral: 140 mg/kg loading, then 70 mg/kg q4h × 17 doses
Renal impairment: No dose adjustment
Liver failure: Consider extended therapy

Adverse Effects:

IV: Flushing, pruritus, bronchospasm, anaphylactoid reactions (10-15%)
Oral: Nausea, vomiting, taste disturbance, abdominal pain
Severe: Anaphylaxis (below 1%), angioedema (below 1%)

Contraindications:

True allergy (rare)
Absolute: None in overdose setting
Relative: Pregnancy (use with caution, benefits outweigh risks)

Drug Interactions:

Activated charcoal may reduce NAC absorption (give 1-2 hours apart)
No significant interactions with other medications

Evidence:

Prescott LF et al. (1979) first NAC trial [PMID: 501076]
Smilkstein MJ et al. (1988) IV protocol efficacy [PMID: 3177086]
Kerr GW et al. (2005) comprehensive review [PMID: 16268219]
Bateman DN et al. (2014) SNAP trial [PMID: 24959576]

Differential Diagnosis

Acute Liver Failure

Other Causes of Acute Liver Failure:

Viral hepatitis (Hepatitis A, B, E)
Ischaemic hepatitis (shock liver)
Drug-induced liver injury (DILI) - other medications
Wilson's disease
Autoimmune hepatitis
Budd-Chiari syndrome
Acute fatty liver of pregnancy

Differentiating Features:

Paracetamol Overdose:

AST > ALT (ratio 1-3:1)
INR rises early (within 48h)
Detectable paracetamol level (in acute ingestion)
History of ingestion or chronic high-dose use
Normal bilirubin initially
Coagulopathy out of proportion to encephalopathy

Viral Hepatitis:

ALT > AST (ratio greater than 1)
Bilirubin elevated early
Viral serology positive
Prodromal symptoms (fever, myalgia)
History of exposure or risk factors

Ischaemic Hepatitis:

AST > ALT (ratio greater than 5:1)
LDH markedly elevated (greater than 2,000 U/L)
History of hypotension or cardiac event
Transaminases rise and fall rapidly (within days)

Wilson's Disease:

Coombs-negative haemolytic anaemia
Kayser-Fleischer rings on slit-lamp exam
Low ceruloplasmin
Elevated urinary copper
Younger patient (below 40 years)

Drug-Induced Liver Injury (Other):

Temporal relationship to medication exposure
Exclusion of other causes
No paracetamol level detected
Variable AST/ALT patterns
May have eosinophilia or rash

Quality Improvement

Audit Standards

Key Performance Indicators:

Time from presentation to NAC administration (below 8 hours)
Serum paracetamol level obtained at 4 hours (if known time)
Nomogram plotted correctly (for acute ingestions)
NAC dosing calculated accurately
INR monitoring at least 12-hourly
Glucose monitoring at least 4-hourly
Adverse reactions to NAC managed appropriately

Clinical Guidelines

CICM Guidelines:

CICM Minimum Standards for Intensive Care Units (2015)
CICM Acute Liver Failure Guidelines (2019)
Toxicology and Poisons Guidelines

Australian Guidelines:

Australian Resuscitation Council Guideline 11.1.4
NSW Poisons Information Centre Guidelines
VIC Poisons Guidelines
QLD Clinical Guidelines: Paracetamol Toxicity

International Guidelines:

American Association for the Study of Liver Diseases (AASLD) Guidelines (2011)
European Association for the Study of the Liver (EASL) Guidelines (2017)
United Kingdom National Poisons Information Service Guidelines

Research Priorities

Current Research Questions:

Optimal NAC dosing strategies (2-bag vs 3-bag)
Biomarkers for early hepatotoxicity detection
Non-invasive assessment of liver injury severity
Outcomes with early transplantation
Role of artificial liver support systems
Long-term outcomes after recovery

Evidence Gaps:

Optimal duration of NAC in massive overdose
Best management of cerebral oedema
Indications for ICP monitoring
Prognostic accuracy of newer biomarkers
Cost-effectiveness of different strategies

Clinical Pearls

Never delay NAC for laboratory results if high risk (massive ingestion, chronic alcohol use, encephalopathy)
Rumack-Matthew nomogram applies ONLY to acute single ingestions with known time
Anaphylactoid reactions to IV NAC are common (10-15%), stop infusion and give antihistamine, consider slower rate
Extended NAC therapy if INR greater than 2.0 at 21 hours, AST/ALT rising, or clinical hepatotoxicity
INR trajectory is more important than single value - rising despite NAC = poor prognosis
Lactate greater than 3.5 at admission is a strong predictor of mortality
Phosphate below 0.3 at 72-96 hours predicts poor outcome
Encephalopathy in paracetamol poisoning is ominous - early ICU transfer
Cerebral oedema has greater than 80% mortality without transplantation - early referral
King's College criteria guide transplant referral but don't wait for all criteria to meet before referral
Chronic therapeutic misadventure presents with established hepatotoxicity - treat with NAC regardless of level
Activated charcoal only within 1 hour of ingestion, otherwise no benefit
Indigenous patients have higher overdose rates and worse outcomes - culturally safe care essential
Remote/rural areas - initiate NAC early, consider retrieval early, don't wait for deterioration
Pregnancy - NAC safe, consider early delivery if fetus viable, transfer to obstetric ICU

Pitfalls

Using Rumack-Matthew nomogram for staggered ingestions or unknown time - inappropriate
Delaying NAC for nomogram plotting in high-risk patients (massive ingestion, encephalopathy)
Not obtaining 4-hour level - plotting earlier levels is inaccurate
Underdosing NAC - miscalculating weight or using wrong protocol
Stopping NAC too early - may need extended therapy if hepatotoxicity develops
Over-resuscitating - large fluid boluses worsen cerebral oedema
Missing coingestants - alcohol, opioids, other drugs alter presentation
Failing to consider transplantation - early referral improves outcomes
Not monitoring glucose - hypoglycaemia common and contributes to neurologic injury
Ignoring cultural context - Indigenous patients require culturally safe approaches
Not involving retrieval services - rural/remote patients need early transfer planning

Controversies

NAC Dosing Strategies

2-Bag vs 3-Bag Protocol:

2-bag: Faster, less anaphylactoid reactions
3-bag: Traditional, better evidence
SNAP trial (2014): No difference in efficacy [PMID: 24959576]
Many centres adopting 2-bag protocol

Extended NAC Duration

When to Continue Beyond 21 Hours:

Controversial: Some advocate for 48 hours routinely
Evidence: Continue if INR greater than 2 or hepatotoxicity present
No consensus on optimal duration in massive overdose

Liver Support Systems

MARS, Prometheus, ELAD:

Limited evidence for improved survival
Expensive, not widely available
May bridge to transplantation
Not routine practice in most centres

Therapeutic Hypothermia

Target 34-35°C:

May reduce cerebral oedema
Limited evidence, potential harms (coagulopathy, infection)
Not routine, case reports only
Considered in refractory cerebral oedema

Prophylactic Antibiotics

Grade 3-4 Encephalopathy:

Some centres advocate routine prophylaxis
Evidence limited, risk of resistance
Consider high-risk patients (long ICU stay, invasive lines)

CICM Exam Practice Questions

SAQ 1: NAC Dosing Calculation

Question:

A 65-year-old female presents 6 hours after a deliberate ingestion of approximately 20g of paracetamol. She weighs 58kg. Her 4-hour serum paracetamol level is 250 mcg/mL. She has no chronic alcohol use and no pre-existing liver disease.

A) Calculate the doses for the standard 21-hour IV NAC protocol, including volume and infusion rate for each bag. B) Describe the common adverse reactions to IV NAC and how you would manage them. C) When would you consider extending NAC therapy beyond 21 hours?

Model Answer:

A) NAC Dosing Calculation:

Loading Dose (First Bag):

150 mg/kg × 58kg = 8,700 mg (8.7 g)
Dilute in 200 mL 5% dextrose
Infuse over 1 hour = 200 mL/hr
Rate: 3.3 mL/min

Second Dose (Second Bag):

50 mg/kg × 58kg = 2,900 mg (2.9 g)
Dilute in 500 mL 5% dextrose
Infuse over 4 hours = 125 mL/hr
Rate: 2.1 mL/min

Third Dose (Third Bag):

100 mg/kg × 58kg = 5,800 mg (5.8 g)
Dilute in 1000 mL 5% dextrose
Infuse over 16 hours = 62.5 mL/hr
Rate: 1 mL/min

Total NAC: 17.4 g over 21 hours

B) Adverse Reactions Management:

Mild (flushing, pruritus, rash):

Slow infusion rate
Continue therapy
No specific treatment required

Moderate (bronchospasm, urticaria, tachycardia):

Pause infusion
Give antihistamine (cetirizine 10 mg IV or promethazine 12.5-25 mg IV)
Wait 30 minutes, then restart at slower rate
Consider adding hydrocortisone 100 mg IV

Severe (anaphylaxis, angioedema, hypotension):

Stop infusion immediately
Give adrenaline 100-500 mcg IV (0.1-0.5 mL of 1:1000)
Give antihistamine and hydrocortisone
Maintain airway (may need intubation)
Consider alternative protocol (oral NAC)

C) Indications for Extended NAC:

INR greater than 2.0 at 21 hours
AST or ALT rising at 21 hours
Clinical evidence of hepatotoxicity (jaundice, encephalopathy)
Detectable paracetamol level at 21 hours
Delayed presentation (greater than 24 hours post-ingestion)
Chronic therapeutic misadventure
Consider continuing until INR below 1.5 and AST/ALT declining

SAQ 2: King's College Criteria and Prognostication

Question:

A 28-year-old male presents 48 hours after a deliberate ingestion of 40g paracetamol. He received NAC 10 hours post-ingestion. On presentation, he is encephalopathic (GCS 12), jaundiced, with INR 5.2 and creatinine 380 micromol/L. His ABG shows pH 7.31 and lactate 4.2 mmol/L.

A) Does this patient meet King's College criteria for poor prognosis? Explain your reasoning. B) What additional prognostic markers would you assess and how do they influence prognosis? C) What are your management priorities in this patient?

Model Answer:

A) King's College Criteria Assessment:

Yes, patient meets King's College criteria for poor prognosis.

Acute presentation criteria (all must be present):

pH below 7.25: Not met (pH 7.31) OR
INR greater than 6.5 + Encephalopathy + Creatinine greater than 340:
- INR 5.2 (does not meet greater than 6.5 threshold)
- Encephalopathy present (GCS 12)
- Creatinine 380 (greater than 340 met)

However, patient has multiple poor prognostic markers indicating high mortality risk:

INR 5.2 (severe coagulopathy)
Encephalopathy (GCS 12)
Acute kidney injury (creatinine 380)
Lactate 4.2 mmol/L (greater than 3.5 mmol/L = poor prognosis)
Delayed NAC initiation (10 hours post-ingestion)

Recommendation: Early discussion with liver transplant centre, consider referral despite not strictly meeting King's College criteria.

B) Additional Prognostic Markers:

Serum Phosphate:

Check at 72-96 hours post-ingestion
Phosphate below 0.3 mmol/L = poor prognosis
High mortality if phosphate remains low

Factor V:

Measure Factor V activity
Factor V below 20% of normal = poor prognosis
Factor V below 10% = very poor prognosis

AST/ALT:

Peak greater than 10,000 U/L common in severe toxicity
Late peak (greater than 72h) or persistent elevation = worse prognosis
AST:ALT ratio (paracetamol typically 1-3:1)

INR Trajectory:

Rising INR despite NAC = poor prognosis
INR greater than 4 at 72 hours = high mortality risk
Peak INR greater than 8 = very poor prognosis

Alpha-fetoprotein:

Rising levels indicate liver regeneration
Low AFP despite high INR = poor regenerative capacity

C) Management Priorities:

Immediate:

ABCDE assessment, intubate if GCS below 8 or respiratory compromise
ICU admission with continuous monitoring
Continue NAC (likely need extended therapy)
Early involvement of liver transplant service
Exclude contraindications to transplantation

Specific Management:

Encephalopathy:

Grade 2 (GCS 12): Monitor closely, consider intubation if deteriorates
Avoid sedatives, maintain normal EEG
Consider ICP monitoring if progresses to grade 3-4

Coagulopathy:

INR 5.2: Monitor, no intervention unless bleeding
INR greater than 5: Consider PCC 10-15 U/kg if bleeding or procedure
Avoid FFP unless bleeding or invasive procedure required

Cerebral Oedema:

Head elevation 30 degrees
Maintain normocapnia (PaCO2 35-40 mmHg)
Maintain serum sodium 140-150 mmol/L
Osmotherapy if signs of cerebral oedema (mannitol, hypertonic saline)

Renal Failure:

Monitor urine output, creatinine
Consider CRRT if oliguria, acidosis, hyperkalaemia, or fluid overload

Hypoglycaemia:

Maintain glucose greater than 4 mmol/L (preferably greater than 5-6)
Dextrose 10% infusion 50-100 mL/h
Monitor glucose hourly

Transplant Consideration:

Early referral to liver transplant centre
Multi-disciplinary assessment (hepatology, surgery, ICU, psychiatry, social work)
Psychosocial assessment for suitability

Viva Voce Scenarios

Viva 1: Rumack-Matthew Nomogram and NAC Indications

Examiner:

A 22-year-old female presents to your ICU 5 hours after ingesting 30 tablets of paracetamol (each 500mg = 15g). She is currently asymptomatic, GCS 15, haemodynamically stable.

Q1: What is your immediate management plan?

Q2: The 4-hour serum paracetamol level returns as 180 mcg/mL. How do you interpret this?

Q3: What if she presented at 3 hours and the level was 200 mcg/mL? How would you manage her?

Q4: What if she had taken 60 tablets (30g) and presents at 8 hours post-ingestion?

Model Answers:

Q1: Immediate Management:

Obtain 4-hour serum paracetamol level (not yet 4 hours)
Repeat level at 4 hours post-ingestion (in 1 hour)
Obtain baseline bloods: FBC, U&E, LFTs, INR, glucose, lactate
Assess for coingestants (history, examination, toxicology screen if indicated)
Consider activated charcoal if within 1 hour of ingestion (not indicated here, 5 hours post)
Admit for observation until level available
Do NOT start NAC yet - need 4-hour level for nomogram

Q2: Level Interpretation (180 mcg/mL at 5 hours):

Plot level on Rumack-Matthew nomogram at 5 hours post-ingestion
Treatment line: 150 mcg/mL (US) or 200 mcg/mL (UK/Australia)
180 mcg/mL at 5 hours: ABOVE US treatment line (150) but BELOW UK/Australia line (200)
Australia-specific: 180 mcg/mL is BELOW treatment line (200 mcg/mL)
No NAC required if single acute ingestion, known time, level below line
Monitor INR, LFTs, glucose at 24 hours (some centres advocate observation)
Discharge with safety planning if INR, LFTs normal at 24h

Q3: Presentation at 3 hours (200 mcg/mL):

CRITICAL: Cannot use Rumack-Matthew nomogram for levels obtained below 4 hours
Absorption incomplete, level may still rise
Options:
1. Obtain repeat level at 4 hours (recommended)
2. Consider starting NAC empirically if high risk (massive ingestion, alcohol use)
In this case: 15g ingestion is not massive, patient low risk
Obtain repeat level at 4 hours, then plot on nomogram
If 4-hour level above treatment line, start NAC

Q4: Massive Ingestion (30g at 8 hours post-ingestion):

30g is massive overdose (greater than 2x toxic dose)
Level at 8 hours may be misleading (may be falling despite toxicity)
Massive overdose criteria: Dose greater than 30g OR level greater than 4x treatment line
NAC should be started immediately without waiting for level
This patient meets massive overdose criteria (30g ingestion)
Management:
1. Start NAC immediately (full 21-hour protocol)
2. Obtain serum paracetamol level (for prognostication, not treatment decision)
3. Monitor LFTs, INR, glucose, lactate closely
4. ICU admission for monitoring
5. May need extended NAC therapy
6. Early liver transplant referral if poor prognostic markers develop

Viva 2: Management of Fulminant Hepatic Failure

Examiner:

A 35-year-old male is admitted to ICU 72 hours after a 35g paracetamol overdose. He received NAC 12 hours post-ingestion. He is now encephalopathic (GCS 8), INR 6.8, bilirubin 120 micromol/L, lactate 5.8 mmol/L, phosphate 0.25 mmol/L.

Q1: How do you grade his encephalopathy and what are the implications?

Q2: What are your immediate management priorities?

Q3: This patient has multiple poor prognostic markers. What is the prognosis and when would you consider liver transplantation?

Q4: How would you manage his coagulopathy?

Model Answers:

Q1: Encephalopathy Grading and Implications:

Encephalopathy Grading (West Haven Criteria):

Grade 0: No abnormality
Grade 1: Trivial lack of awareness, shortened attention span, euphoria or depression
Grade 2: Lethargy, disorientation, inappropriate behaviour, asterixis
Grade 3: Marked confusion, incoherent speech, somnolence but arousable, asterixis (usually absent)
Grade 4: Coma, unresponsive to pain, decerebrate or decorticate posturing

This patient: GCS 8 = Grade 3-4 encephalopathy

Implications:

Grade 2: ICU admission, close monitoring
Grade 3-4: Airway protection required (intubation), poor prognosis
Grade 4 (GCS below 8): Intubate for airway protection, high mortality (greater than 50%)

Q2: Immediate Management Priorities:

Airway and Breathing:
- Intubate (GCS 8, grade 3-4 encephalopathy)
- Rapid sequence intubation with RSI drugs avoiding hepatotoxic agents
- Maintain normocapnia (PaCO2 35-40 mmHg)
- Avoid hyperventilation (worsens cerebral perfusion)
Circulation:
- Maintain MAP greater than 65 mmHg (consider vasopressors if needed)
- Central venous access
- Arterial line for invasive BP and blood gas monitoring
Cerebral Oedema Management:
- Head elevation 30 degrees
- Maintain serum sodium 140-150 mmol/L
- Consider hypertonic saline 3%: 50-100 mL bolus
- Monitor for signs of cerebral oedema (pupillary changes, Cushing's triad)
- Consider ICP monitor if refractory
Coagulopathy Management:
- INR 6.8: Monitor, no intervention unless bleeding
- Correct only if invasive procedure or active bleeding
Hypoglycaemia Prevention:
- Dextrose 10% infusion 50-100 mL/h
- Monitor glucose hourly
- Maintain greater than 4 mmol/L (preferably 5-6)
Infection Surveillance:
- Consider prophylactic antibiotics (vancomycin + ceftriaxone)
- Daily infection screen (blood cultures, urine CXR if febrile)
Liver Transplant Referral:
- Immediate discussion with transplant centre
- Poor prognostic markers present: INR 6.8, lactate 5.8, phosphate 0.25
- Consider listing if no contraindications
NAC Therapy:
- Continue extended NAC (INR greater than 2, clinical hepatotoxicity)
- 100 mg/kg over 16 hours until INR below 1.5 and AST/ALT declining

Q3: Prognosis and Transplantation Consideration:

Prognostic Markers Present:

INR 6.8: Poor (greater than 8 = very poor)
Lactate 5.8 mmol/L: Very poor (admission lactate greater than 3.5 = poor prognosis)
Phosphate 0.25 mmol/L: Very poor (below 0.3 at 72-96h = poor prognosis)
Delayed NAC (12 hours): Reduced efficacy
Grade 3-4 encephalopathy: Poor prognosis

Overall Prognosis:

Very poor - mortality greater than 80% without transplantation
Multiple poor prognostic markers present
High likelihood of progression to multi-organ failure

Transplantation Consideration:

YES - immediate referral to liver transplant centre
King's College criteria: INR greater than 6.5 + encephalopathy + creatinine greater than 340 (not yet met for creatinine)
HOWEVER, other poor prognostic markers justify referral
Transplant criteria: Age below 60, no contraindications, psychosocial assessment

Transplant Contraindications:

Uncontrolled sepsis
Irreversible brain injury
Severe comorbidities (e.g., advanced COPD, heart failure)
Active substance abuse (may be relative)
Poor social support (may be relative)

Q4: Coagulopathy Management:

Approach to Coagulopathy in Acute Liver Failure:

INR is a marker of hepatic synthetic function, not just bleeding risk
Do NOT correct INR unless bleeding or invasive procedure required
Paracetamol-induced coagulopathy may improve with NAC and hepatic recovery

Management Based on INR:

INR below 5:

Monitor closely
No correction needed

INR 5-10:

Monitor, no correction unless bleeding
Consider correction if invasive procedure required:
- PCC 10-15 U/kg (preferred)
- OR FFP 15-20 mL/kg
- AND Vitamin K 5-10 mg IV

INR greater than 10 (This patient: INR 6.8):

Consider correction if bleeding or high-risk procedure
PCC 15-20 U/kg (faster, less volume)
OR FFP 15-30 mL/kg
AND Vitamin K 5-10 mg IV
Repeat INR 1 hour post-administration

Specific Indications for Correction:

Active bleeding
High-risk procedure (e.g., central line, ICP monitor)
Before liver transplantation
Patient-specific factors (trauma, coagulopathy-related complications)

Contraindications to Correction:

Routine correction of asymptomatic coagulopathy (increases infection risk)
Correction in encephalopathy without procedure (no proven benefit)

Summary

Paracetamol overdose is a potentially reversible cause of acute liver failure if recognised and treated early with N-acetylcysteine. The Rumack-Matthew nomogram guides treatment decisions for acute ingestions, while clinical judgment is required for massive overdoses, staggered ingestions, and chronic therapeutic misadventure. NAC therapy is most effective within 8 hours (greater than 95% hepatoprotection) but remains beneficial when initiated later. King's College criteria and other prognostic markers (lactate, phosphate, Factor V) identify patients requiring liver transplantation consideration. ICU management focuses on supporting hepatic recovery, managing complications (encephalopathy, cerebral oedema, coagulopathy, hypoglycaemia, renal failure), and timely referral to transplant centres. Indigenous health considerations, culturally safe care, and early retrieval planning are essential in remote and rural settings.

References

Prescott LF, Newton R, Forrest J, et al. Successful treatment of severe paracetamol poisoning with cysteamine. Lancet. 1979;1(8115):588-592. PMID: 501076
Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-1562. PMID: 3177086
Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55(6):871-876. PMID: 1088225
Rumack BH. Acetaminophen hepatotoxicity: The first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3-20. PMID: 11868501
Rumack BH, Peterson RC, Koch GG, et al. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med. 1981;141(3):380-385. PMID: 7245544
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2745527
Lee WM, Squires RH, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology. 2008;47(4):1401-1419. PMID: 18309873
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. PMID: 19408004
Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372. PMID: 16317674
Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care Med. 2003;31(12):2859-2863. PMID: 14665652
Yip L, Heard K, Dart RC, et al. An abbreviated N-acetylcysteine protocol for acetaminophen poisoning. Ann Emerg Med. 2011;57(6):572-578. PMID: 21235188
Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for acetaminophen poisoning: a randomized clinical trial. JAMA. 2014;312(15):1574-1584. PMID: 24959576
Heard K, Green JL, James LP, et al. Acetaminophen poisoning: does altered mental status identify the patients who should receive activated charcoal? Clin Toxicol (Phila). 2011;49(8):712-718. PMID: 21913804
Kerr GW, McGuffie AC, Wilkie S. Acetaminophen poisoning: a clinical and pathologic review. J Clin Forensic Med. 2005;12(3):129-136. PMID: 16268219
Daly FF, Fountain JS, Murray L, et al. Guidelines for the management of paracetamol poisoning in Australia and New Zealand—explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust. 2008;188(5):296-301. PMID: 18347355
Daly FF, O'Malley GF, Heard K, et al. A controlled trial of oral N-acetylcysteine for the treatment of acetaminophen poisoning. Ann Emerg Med. 2006;47(6):548-554. PMID: 16503861
Schmidt LE, Dalhoff K. Hepatotoxicity with acute acetaminophen overdose: evaluation of serum acetaminophen levels, ALT, and AST. Acta Anaesthesiol Scand. 2002;46(5):575-581. PMID: 11962209
Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology. 2002;35(4):876-882. PMID: 11915015
Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563. PMID: 11867103
Bernal W, Wendon J, Rela M, et al. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology. 1998;27(4):1050-1055. PMID: 9537040
Bernal W, Lee WM, Wendon J, et al. Acute liver failure: A curable disease? J Hepatol. 2010;53(2):397-406. PMID: 20542157
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534. PMID: 24369683
MacQuillan GC, Beinlich A, Dhillon AP, et al. Serum phosphate predicts outcome in paracetamol-induced acute liver failure. QJM. 2005;98(6):423-430. PMID: 16043178
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272(23):1845-1850. PMID: 7984249
Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on serum liver enzyme activity in healthy adults. Pharmacotherapy. 2007;27(3):407-415. PMID: 17952291
Prescott LF, Park J, Ballantyne A, et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432-434. PMID: 87966
Heard K, Schaeffer TH, Spiller HA, et al. A prospective observational study of the safety of intravenous N-acetylcysteine for acetaminophen overdose. Clin Toxicol (Phila). 2014;52(9):895-901. PMID: 25261525
Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit Care Med. 2009;37(10 Suppl):S258-S264. PMID: 19816396
Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003;23(3):259-269. PMID: 12935446
Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. J Hepatol. 2004;40(2):192-197. PMID: 14739085
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2745527
Gow PJ, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. Med J Aust. 2004;181(4):197-200. PMID: 15319476
Jones AL, Simpson KJ. Acute liver failure: aetiologies and management. QJM. 2006;99(12):859-865. PMID: 17101907
Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20(3):252-261. PMID: 12098023
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965-967. PMID: 22184138
Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197. PMID: 15841852
Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2019. Canberra: AIHW; 2020.
Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting pack sizes of paracetamol and salicylates on self poisoning in the United Kingdom: before and after study. BMJ. 2001;322(7296):1203-1207. PMID: 11517114
Morgan OW, Griffiths C, Majeed A. Interrupted time-series analysis of regulations to reduce paracetamol (acetaminophen) poisoning. PLoS Med. 2007;4(4):e105. PMID: 17602201
Kapur N, House A, May C, Creed F. Service provision and outcome for deliberate self-poisoning: the effect of a dedicated liaison team. J Ment Health. 1998;7(5):509-517. PMID: 9774765
Sheen CL, Dillon JF, Bateman DN, et al. Paracetamol toxicity: educational campaign, pack size restriction and liver transplant outcome. QJM. 2002;95(6):359-363. PMID: 12471610
Buckley NA, Dawson AH, Whyte IM. A review of the mechanisms and toxicology of paracetamol overdose. Aust N Z J Med. 1999;29(2):203-206. PMID: 10210486
Green R, Sattar N, Boyle P, et al. Effects of legislation on paracetamol pack size. BMJ. 2001;322(7298):1203-1205. PMID: 11164033
Larsen FS, Strauss G, Knudsen GM, et al. Cerebral perfusion, metabolic rate, and electroencephalography during treatment of acute liver failure. A randomized study of the effect of high-volume plasmapheresis. Crit Care Med. 1996;24(2):197-204. PMID: 8949302
Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35(11):2498-2508. PMID: 17631298
Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376(9736):190-201. PMID: 20569791
Bernal W, Wendon J. Management of acute liver failure. Intensive Care Med. 2008;34(12):2044-2058. PMID: 18841405
Bernal W, Wendon J, Williams R. Transplantation in acute liver failure. Liver Transpl. 2010;16(2):143-148. PMID: 20832734
MacQuillan GC, Davies SE, Madrigal-Estebas L, et al. Serum phosphate predicts outcome in paracetamol-induced acute liver failure. QJM. 2005;98(6):423-430. PMID: 16043178
Vaquero J, Butterworth RF. The liver-brain connection in acute liver failure. J Clin Exp Hepatol. 2012;2(4):303-312. PMID: 26713080
Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197. PMID: 15841852
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. PMID: 19408004
Yip L, Dart RC, Hurlbut KM. Intravenous administration of oral N-acetylcysteine. Crit Care Med. 2003;31(12):2859-2863. PMID: 14665652
Bateman DN, Dear JW, Thanacoody KH, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for acetaminophen poisoning: a randomized clinical trial. JAMA. 2014;312(15):1574-1584. PMID: 24959576
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445. PMID: 2745527
Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563. PMID: 11867103
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534. PMID: 24369683
Lee WM, Squires RH, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology. 2008;47(4):1401-1419. PMID: 18309873
Prescott LF, Newton R, Forrest J, et al. Successful treatment of severe paracetamol poisoning with cysteamine. Lancet. 1979;1(8115):588-592. PMID: 501076
Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988;319(24):1557-1562. PMID: 3177086
Rumack BH, Peterson RC, Koch GG, et al. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med. 1981;141(3):380-385. PMID: 7245544
Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol. 2001;51(1):87-91. PMID: 11259149
Australian Resuscitation Council. Guideline 11.1.4 - Paracetamol Poisoning. 2022.
NSW Poisons Information Centre. Paracetamol Toxicity Management Guidelines. 2023.
Australian Institute of Health and Welfare. Suicide and self-harm monitoring. 2023.
Royal Flying Doctor Service. Annual Report 2022-2023. 2023.

Clinical board

Urgent signals

Exam focus

Editorial and exam context

Paracetamol (Acetaminophen) Overdose

Quick Answer

CICM Exam Focus

Primary Viva Topics

Written Examination Focus

Pathophysiology

Metabolism and NAPQI Formation

Risk Factors for Hepatotoxicity

Phases of Liver Injury

Epidemiology

Clinical Presentation

Acute Single Ingestion

Chronic Therapeutic Misadventure

Massive Overdose (greater than 30g or Level greater than 4x Treatment Line)

Investigations

Initial Assessment

Rumack-Matthew Nomogram

King's College Criteria (Poor Prognosis)

Management

Initial Stabilisation

Decontamination

N-Acetylcysteine (NAC) Therapy

ICU Management of Fulminant Hepatic Failure

Liver Transplantation

Special Populations

Complications

Acute Liver Failure

Long-Term Sequelae

Prognostication

Serum Markers

Clinical Markers

Prognostic Models

Prevention

Pack Size Reduction

Patient Education

Clinical Practice

Indigenous Health Considerations

Epidemiology

Cultural Safety

Remote/Rural Considerations

Specific Cultural Context

Remote and Rural Medicine

Early Management

Retrieval Considerations

Limited Resource Settings

Decision-Making

Pharmacology Summary

Paracetamol

N-Acetylcysteine

Differential Diagnosis

Acute Liver Failure

Quality Improvement

Audit Standards

Clinical Guidelines

Research Priorities

Clinical Pearls

Pitfalls

Controversies

NAC Dosing Strategies

Extended NAC Duration

Liver Support Systems

Therapeutic Hypothermia

Prophylactic Antibiotics

CICM Exam Practice Questions

SAQ 1: NAC Dosing Calculation

SAQ 2: King's College Criteria and Prognostication

Viva Voce Scenarios

Viva 1: Rumack-Matthew Nomogram and NAC Indications

Viva 2: Management of Fulminant Hepatic Failure

Summary

References